Silence Competitors

Pink Sheets . USA . 
Stock . Silence Therapeutics plc
SLNCF Stock  USD 1.20  0.12  11.11%   
Silence Therapeutics plc competes with Hansa Biopharma, Transgene, Santhera Pharmaceuticals, Genfit SA, and Mayne Pharma; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Silence Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Silence Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Silence Therapeutics Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Silence Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Silence Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.061.208.68
Details
Intrinsic
Valuation
LowRealHigh
0.061.158.63
Details

Silence Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Silence Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Silence and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Silence Therapeutics plc does not affect the price movement of the other competitor.

High positive correlations

ORYZF
+ 0.8
HNSBF
JWCTF
+ 0.8
MAYNF
BRIBF
+ 0.79
OPORF
MAYNF
+ 0.76
HNSBF
ORYZF
+ 0.75
MAYNF
CMVLF
+ 0.75
ORYZF
  

High negative correlations

JWCTF
- 0.99
TRGNF
BRIBF
- 0.92
GNFTF
CMVLF
- 0.89
SPHDF
GNFTF
- 0.84
OPORF
ORYZF
- 0.83
SPHDF
MAYNF
- 0.8
TRGNF

Risk-Adjusted Indicators

There is a big difference between Silence Pink Sheet performing well and Silence Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Silence Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
HNSBF  1.09 (0.52) 0.00  1.27  0.00 
 0.00 
 0.00 
 0.00 
 36.46 
TRGNF  1.62  0.67  0.00  2.15  0.00 
 0.00 
 0.00 
 0.00 
 61.69 
SPHDF  0.26  0.05  0.00 (0.01) 0.00 
 0.00 
 0.00 
 0.00 
 8.71 
OPORF  1.91 (0.88) 0.00  0.85  0.00 
 0.00 
 0.00 
 0.00 
 64.13 
GNFTF  1.58  0.86  0.00 (1.18) 0.00 
 0.00 
 0.00 
 0.00 
 34.56 
MAYNF  3.26 (0.48) 0.00  0.63  0.00 
 0.00 
 8.63 
(9.75)
 46.83 
ORYZF  0.21 (0.15) 0.00 (0.30) 0.00 
 0.00 
 0.00 
 0.00 
 6.93 
JWCTF  0.98 (0.29) 0.00  2.48  0.00 
 0.00 
 0.00 
 0.00 
 20.00 
BRIBF  0.62 (0.30) 0.00  0.98  0.00 
 0.00 
 0.00 
 0.00 
 20.83 
CMVLF  0.55  0.11  0.00 (0.18) 0.00 
 0.00 
 0.00 
 0.00 
 29.02 
All Fundamental Data

Silence Therapeutics Competitive Analysis

The better you understand Silence Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Silence Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Silence Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SLNCF HNSBF TRGNF SPHDF OPORF GNFTF MAYNF ORYZF JWCTF BRIBF
 11.11 
 1.20 
Silence
 0.00 
 2.91 
Hansa
 0.00 
 1.00 
Transgene
 0.00 
 13.35 
Santhera
 0.00 
 0.09 
Open
 0.00 
 6.00 
Genfit
 8.63 
 2.14 
Mayne
 0.00 
 3.36 
Oryzon
 5.88 
 0.36 
JWCTF
 0.00 
 0.19 
Brii
Market Volatility
(90 Days Market Risk)
Abnormally volatile
Very risky
Abnormally volatile
Very steady
Out of control
Relatively risky
Dangerous
Somewhat reliable
Out of control
Out of control
Market Performance
(90 Days Performance)
Weakest
Weakest
Fair
Fair
Weakest
Good
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Small
Strong
High
Low
Low
High
Small
Moderate
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Under Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Hold
Strong Sell
Strong Sell
Current Ratio
3.76
6.42
4.27
0.75
1.19
6.33
0.84
3.76
9.9
10.68
Net Asset
96.19 M
1.01 B
101.84 M
91.12 M
42.27 M
281.72 M
1.29 B
95.38 M
3.12 B
3.61 B
Profit Margin
-2.24
N/A
-1.27
N/A
-0.0307
0.51
-0.62
-0.33
N/A
N/A
EBITDA
(45.42 M)
(538.83 M)
(16.55 M)
(34.57 M)
3.07 M
79.34 M
(104.64 M)
(6.58 M)
(691.51 M)
(4.18 B)
Operating Margin
-2.99
N/A
-1.39
-386.18
0.0135
0.48
-0.17
-0.72
-8.05
-10.33
Current Valuation
240.14 M
189.89 M
152.15 M
60.45 M
80.15 M
32.19 M
448.85 M
106.94 M
55.09 M
305.78 M
Price To Book
8.36
6.59
0.0177
2.75
2.64
1.36
0.73
1.77
0.64
0.95
Current Asset
N/A
105 M
51 M
74 M
N/A
105 M
N/A
N/A
N/A
N/A
Retained Earnings
N/A
N/A
(500 M)
(291 M)
N/A
(81 M)
N/A
N/A
N/A
N/A
Beta
0.85
0.88
0.79
0.8
1.17
0.98
1.0
1.02
2.04
N/A
Number Of Employees
105
150
143
39
218
134
31
43
589
123
Shares Outstanding
107.68 M
52.44 M
100.2 M
61.81 M
671.05 M
49.82 M
1.74 B
55.26 M
411.01 M
723.35 M
Cash Flow From Operations
6.81 M
(481.17 M)
(31.94 M)
(37.36 M)
(1.56 M)
99.92 M
(7.21 M)
(3.63 M)
(561.2 M)
(879.46 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
0.2
N/A
N/A
N/A
Total Debt
52 K
N/A
N/A
25.8 M
2.26 M
72.05 M
413.67 M
10.35 M
95 M
17.47 M
Return On Equity
-1.43
-0.89
-0.36
-13.16
-0.05
0.67
-0.41
-0.0685
-0.29
-5.34
Z Score
N/A
N/A
-5.6
-3.0
25.2
1.8
N/A
7.8
1.8
28.5
Return On Asset
-0.28
-0.27
-0.16
-0.49
0.0066
0.15
-0.0328
-0.0419
-0.15
-0.19
Book Value Per Share
0.95
1.5
0.55
-0.25
0.031
2.2
0.32
1.35
6.51
4.43
Current Liabilities
N/A
19 M
24 M
10 M
N/A
12 M
N/A
N/A
N/A
N/A
Total Asset
96.19 M
1.01 B
101.84 M
91.12 M
42.27 M
281.72 M
1.29 B
95.38 M
3.12 B
3.61 B
Debt To Equity
0.022
2.29
0.25
N/A
0.11
0.68
0.74
0.25
0.057
0.005
Target Price
938.67
N/A
N/A
N/A
N/A
7.27
N/A
N/A
N/A
N/A
Shares Owned By Institutions
27.7
41.33
1.7
3.5
6.45
2.43
18.64
0.72
4.18
53.1
Market Capitalization
349.96 M
274.8 M
212.74 M
74.18 M
96.91 M
233.59 M
235.41 M
143.68 M
291.45 M
941.75 M
Price To Earning
-17.5
-46.57
-7.42
-6.8
N/A
4.96
11.25
N/A
N/A
N/A
Price To Sales
21.67
16.29
10.71
469.19
2.93
1.87
0.65
13.4
2.8
10.64
Net Income
(39.41 M)
(548.28 M)
(19.54 M)
(55.53 M)
(74 K)
67.26 M
(263.34 M)
(4.69 M)
(702.33 M)
(4.16 B)
Earnings Per Share
-0.53
-0.65
-0.23
-1.68
N/A
0.89
-0.034
-0.093
-0.26
-1.41
Shares Owned By Insiders
56.74
7.37
N/A
18.77
40.93
13.22
22.62
18.04
43.8
5.41
Revenue
12.41 M
33.88 M
9.99 M
(1.59 M)
36.86 M
80.07 M
423.92 M
N/A
30.8 M
N/A
Working Capital
N/A
86 M
27 M
64 M
N/A
93 M
N/A
N/A
N/A
N/A
Cash And Equivalents
51.56 M
60.15 M
49.57 M
21.21 M
15.93 M
209.12 M
98.01 M
28.72 M
1.55 B
3.22 B
Cash Per Share
0.57
1.58
0.5
0.43
0.02
4.21
0.06
0.54
3.78
4.45
Gross Profit
4.96 M
116.05 M
(15.87 M)
(5.36 M)
4.29 M
85.58 M
171.03 M
9.87 M
9.04 M
92.54 M
Daily Balance Of Power
9.2 T
0.0
0.0
0.0
0.0
0.0
9.2 T
0.0
9.2 T
0.0
Day Typical Price
1.2
2.91
1.0
13.35
0.0861
6.0
2.14
3.36
0.36
0.19
Period Momentum Indicator
0.12
N/A
N/A
N/A
N/A
N/A
0.17
N/A
0.02
N/A
Rate Of Daily Change
1.11
1.0
1.0
1.0
1.0
1.0
1.09
1.0
1.06
1.0
Day Median Price
1.2
2.91
1.0
13.35
0.0861
6.0
2.14
3.36
0.36
0.19
Price Action Indicator
0.06
N/A
N/A
N/A
N/A
N/A
0.085
N/A
0.01
N/A
Coefficient Of Variation
16629.83
(812.40)
951.45
10576.3
(812.40)
552.16
(1,252)
(812.40)
(1,044)
(812.40)
Mean Deviation
2.76
1.09
1.62
0.2636
1.91
1.58
3.26
0.2067
0.9813
0.6217
Jensen Alpha
0.1063
(0.52)
0.6708
0.0455
(0.88)
0.861
(0.48)
(0.15)
(0.29)
(0.30)
Total Risk Alpha
(1.00)
(1.15)
(0.18)
(0.19)
(2.01)
0.217
(1.47)
(0.23)
(0.69)
(0.66)
Standard Deviation
7.99
4.49
6.76
1.45
7.89
4.47
6.94
0.8524
3.01
2.56
Kurtosis
18.31
66.0
63.54
32.89
66.0
45.31
9.91
66.0
30.13
66.0
Potential Upside
12.5
N/A
N/A
N/A
N/A
N/A
8.63
N/A
N/A
N/A
Treynor Ratio
(0.05)
1.27
2.15
(0.01)
0.8478
(1.18)
0.6347
(0.30)
2.48
0.9842
Maximum Drawdown
71.0
36.46
61.69
8.71
64.13
34.56
46.83
6.93
20.0
20.83
Variance
63.83
20.14
45.67
2.11
62.3
19.99
48.11
0.7266
9.06
6.58
Market Risk Adjusted Performance
(0.04)
1.28
2.16
0.002
0.8578
(1.17)
0.6447
(0.29)
2.49
0.9942
Risk Adjusted Performance
0.0133
(0.08)
0.0818
0.0118
(0.08)
0.134
(0.05)
(0.08)
(0.06)
(0.08)
Skewness
(2.62)
(8.12)
7.88
0.9342
(8.12)
6.48
(2.00)
(8.12)
(4.27)
(8.12)
Information Ratio
(0.01)
(0.15)
0.0903
(0.06)
(0.14)
0.1587
(0.09)
(0.24)
(0.13)
(0.16)
Value At Risk
(11.11)
N/A
N/A
N/A
N/A
N/A
(9.75)
N/A
N/A
N/A

Silence Therapeutics Competition Performance Charts

Five steps to successful analysis of Silence Therapeutics Competition

Silence Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Silence Therapeutics plc in relation to its competition. Silence Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Silence Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Silence Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Silence Therapeutics plc, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Silence Therapeutics position

In addition to having Silence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Software Thematic Idea Now

Software
Software Theme
Companies that develop and distribute software and software systems to individuals or business. The Software theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Software Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Silence Pink Sheet

When determining whether Silence Therapeutics plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:
How To Invest In Silence
Details
Is Silence Pink Sheet a good investment?
Details
What is Silence Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Silence Therapeutics Correlation with its peers.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY